Cargando…

The incidence and mortality of lung cancer in China: a trend analysis and comparison with G20 based on the Global Burden of Disease Study 2019

BACKGROUND: Lung cancer is a significant health concern in China. There is limited available data of its burden and trends. This study aims to evaluate the trends of lung cancer across different age groups and genders in China and the Group of Twenty (G20) countries, explore the risk factors, and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Jianhai, Zhai, Mimi, Jiang, Qin, Li, Jiyang, Xu, Cixian, Chen, Duo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446846/
https://www.ncbi.nlm.nih.gov/pubmed/37621689
http://dx.doi.org/10.3389/fonc.2023.1177482
_version_ 1785094414860812288
author Long, Jianhai
Zhai, Mimi
Jiang, Qin
Li, Jiyang
Xu, Cixian
Chen, Duo
author_facet Long, Jianhai
Zhai, Mimi
Jiang, Qin
Li, Jiyang
Xu, Cixian
Chen, Duo
author_sort Long, Jianhai
collection PubMed
description BACKGROUND: Lung cancer is a significant health concern in China. There is limited available data of its burden and trends. This study aims to evaluate the trends of lung cancer across different age groups and genders in China and the Group of Twenty (G20) countries, explore the risk factors, and predict the future trends over a 20-year period. METHODS: The data were obtained from the GBD study 2019. The number of cases, age standardized rate (ASR), and average annual percentage changes (AAPC) were used to estimate the trend in lung cancer by age, gender, region and risk factor. The trend of lung cancer was predicted by autoregressive integrated moving average (ARIMA) model by the “xtarimau” command. The joinpoint regression analysis was conducted to identify periods with the highest changes in incidence and mortality. Additionally, the relationship between AAPCs and socio-demographic index (SDI) was explored. RESULTS: From 1990 to 2019, both the incidence and mortality of lung cancer in China and G20 significantly increased, with China experiencing a higher rate of increase. The years with the highest increase in incidence of lung cancer in China were 1998-2004 and 2007-2010. Among the G20 countries, the AAPC in incidence and mortality of lung cancer in the Republic of Korea was the highest, followed closely by China. Although India exhibited similarities, its AAPC in lung cancer incidence and mortality rates was lower than that of China. The prediction showed that the incidence in China will continue to increase. In terms of risk factors, smoking was the leading attributable cause of mortality in all countries, followed by occupational risk and ambient particulate matter pollution. Notably, smoking in China exhibited the largest increase among the G20 countries, with ambient particulate matter pollution ranking second. CONCLUSION: Lung cancer is a serious public health concern in China, with smoking and environmental particulate pollution identified as the most important risk factors. The incidence and mortality rates are expected to continue to increase, which places higher demands on China’s lung cancer prevention and control strategies. It is urgent to tailor intervention measures targeting smoking and environmental pollution to contain the burden of lung cancer.
format Online
Article
Text
id pubmed-10446846
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104468462023-08-24 The incidence and mortality of lung cancer in China: a trend analysis and comparison with G20 based on the Global Burden of Disease Study 2019 Long, Jianhai Zhai, Mimi Jiang, Qin Li, Jiyang Xu, Cixian Chen, Duo Front Oncol Oncology BACKGROUND: Lung cancer is a significant health concern in China. There is limited available data of its burden and trends. This study aims to evaluate the trends of lung cancer across different age groups and genders in China and the Group of Twenty (G20) countries, explore the risk factors, and predict the future trends over a 20-year period. METHODS: The data were obtained from the GBD study 2019. The number of cases, age standardized rate (ASR), and average annual percentage changes (AAPC) were used to estimate the trend in lung cancer by age, gender, region and risk factor. The trend of lung cancer was predicted by autoregressive integrated moving average (ARIMA) model by the “xtarimau” command. The joinpoint regression analysis was conducted to identify periods with the highest changes in incidence and mortality. Additionally, the relationship between AAPCs and socio-demographic index (SDI) was explored. RESULTS: From 1990 to 2019, both the incidence and mortality of lung cancer in China and G20 significantly increased, with China experiencing a higher rate of increase. The years with the highest increase in incidence of lung cancer in China were 1998-2004 and 2007-2010. Among the G20 countries, the AAPC in incidence and mortality of lung cancer in the Republic of Korea was the highest, followed closely by China. Although India exhibited similarities, its AAPC in lung cancer incidence and mortality rates was lower than that of China. The prediction showed that the incidence in China will continue to increase. In terms of risk factors, smoking was the leading attributable cause of mortality in all countries, followed by occupational risk and ambient particulate matter pollution. Notably, smoking in China exhibited the largest increase among the G20 countries, with ambient particulate matter pollution ranking second. CONCLUSION: Lung cancer is a serious public health concern in China, with smoking and environmental particulate pollution identified as the most important risk factors. The incidence and mortality rates are expected to continue to increase, which places higher demands on China’s lung cancer prevention and control strategies. It is urgent to tailor intervention measures targeting smoking and environmental pollution to contain the burden of lung cancer. Frontiers Media S.A. 2023-08-09 /pmc/articles/PMC10446846/ /pubmed/37621689 http://dx.doi.org/10.3389/fonc.2023.1177482 Text en Copyright © 2023 Long, Zhai, Jiang, Li, Xu and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Long, Jianhai
Zhai, Mimi
Jiang, Qin
Li, Jiyang
Xu, Cixian
Chen, Duo
The incidence and mortality of lung cancer in China: a trend analysis and comparison with G20 based on the Global Burden of Disease Study 2019
title The incidence and mortality of lung cancer in China: a trend analysis and comparison with G20 based on the Global Burden of Disease Study 2019
title_full The incidence and mortality of lung cancer in China: a trend analysis and comparison with G20 based on the Global Burden of Disease Study 2019
title_fullStr The incidence and mortality of lung cancer in China: a trend analysis and comparison with G20 based on the Global Burden of Disease Study 2019
title_full_unstemmed The incidence and mortality of lung cancer in China: a trend analysis and comparison with G20 based on the Global Burden of Disease Study 2019
title_short The incidence and mortality of lung cancer in China: a trend analysis and comparison with G20 based on the Global Burden of Disease Study 2019
title_sort incidence and mortality of lung cancer in china: a trend analysis and comparison with g20 based on the global burden of disease study 2019
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446846/
https://www.ncbi.nlm.nih.gov/pubmed/37621689
http://dx.doi.org/10.3389/fonc.2023.1177482
work_keys_str_mv AT longjianhai theincidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019
AT zhaimimi theincidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019
AT jiangqin theincidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019
AT lijiyang theincidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019
AT xucixian theincidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019
AT chenduo theincidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019
AT longjianhai incidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019
AT zhaimimi incidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019
AT jiangqin incidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019
AT lijiyang incidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019
AT xucixian incidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019
AT chenduo incidenceandmortalityoflungcancerinchinaatrendanalysisandcomparisonwithg20basedontheglobalburdenofdiseasestudy2019